JAMA Oncology

Displaying 1 - 1 of 1

Study tracks incidence, timing of immunotherapy-related deaths

Study tracks incidence, timing of immunotherapy-related deaths

Related Categories: 
checkpoint inhibitors douglas johnson immunotherapy JAMA Oncology NIH Vanderbilt Ingram Cancer Center